Figure 5 | Scientific Reports

Figure 5

From: Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA markers in urothelial bladder cancer patients

Figure 5

Recurrence-free survival curve analysis of the LV phase. Patients were stratified by EV KRT17 in urine obtained before TUR (CSV phase) (A) or during the first 6 months after TUR (LV phase) (B) using the threshold defined in the CSV phase (Table 3), and recurrence-free survival was compared between EV KRT17 positives and negatives. Patients were also stratified by the average score of EV KRT17, cytology, and microhematuria during the first 6 months after TUR (LV phase) using a cut-off of 0.5 (C). The significance of differences was assessed by the Log-rank test. Censored patients were indicated by crosses in the curves. (A) EV KRT17, CSV phase (B) EV KRT17, LV phase (<6 months) (C) Combination (EV KRT17+Cytology+Microhematurial), LV phase (<6 months)

Back to article page